[Giant cell tumor of bone]

Area of Science:

• Orthopedic Oncology
• Bone Pathology
• Pharmacological Treatments

Background:

• Giant cell tumor (GCT) is a benign epiphyseo-metaphyseal bone tumor common in young individuals.
• Characterized by extensive osteolysis, GCTs have a high recurrence rate, risk of malignant transformation, and potential for pulmonary metastases.
• Standard treatments include curettage with cavity filling, or wide resection with prosthetic reconstruction for severe cases.

Purpose of the Study:

• To review the pathophysiology of giant cell tumors, focusing on the role of RANK-L.
• To evaluate the efficacy and application of denosumab in managing GCTs.
• To inform treatment strategies for aggressive and inoperable GCTs.

Main Methods:

• Literature review on GCT pathophysiology and RANK-L signaling.
• Analysis of clinical trial data for denosumab in GCT treatment.
• Case study review of denosumab application in specific anatomical locations.

Main Results:

• Understanding the role of RANK-L has opened new therapeutic avenues for GCTs.
• Denosumab has demonstrated efficacy in treating inoperable or aggressive GCTs.
• Pre-operative denosumab treatment is beneficial for lesions in the spine, pelvis, and sacrum before en bloc resection.

Conclusions:

• Denosumab represents a significant advancement in managing challenging giant cell tumors.
• Targeting RANK-L with denosumab offers a targeted therapy for GCTs.
• This approach is particularly valuable for high-risk lesions, improving surgical outcomes and patient prognosis.